Results: Overall anti-JCV antibody seroprevalence was 60.8% (95% confidence interval, 56.9-64.5). Seroprevalence was associated with higher age (P = 0.030) and was lower in natalizumab-treated patients (P < 0.001). The mean anti-JCV antibody index of immunosuppressant-naive patients was 1.5 ± 1.3 (n = 378). The main reasons for performing the test were clinical characterization (35.5%) and medication change (26.2%). In patients who switched treatments (n = 109), fingolimod (47.7%) and natalizumab (26.6%) were the most commonly chosen new treatments.
Introduction
Multiple sclerosis (MS) is a chronic, inflammatory and degenerative demyelinating disease of the central nervous system (CNS) with a multifactorial aetiology that has not yet been fully elucidated [1, 2] . With an estimated global prevalence of 33 per 100,000, MS is in many countries the leading cause of nontraumatic neurologic disability among young adults, and it has a significant social and economic impact [3] [4] [5] . In Portugal, MS is estimated to affect approximately 40-50 per 100,000 inhabitants [6] [7] [8] .
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the CNS that can result in death or severe disability [9, 10] . PML is caused by JC virus (JCV), a human polyomavirus that individuals are commonly exposed to early in life and that usually results in a subclinical infection [9, 10] . JCV infection results in production of anti-JCV antibodies detectable in the blood or serum [11] . JCV activation and PML generally occur only in patients who are immunocompromised or being treated with certain immunosuppressive/immunomodulatory treatments. Natalizumab (Tysabri ® , Biogen), a monoclonal antibody approved as therapy for active relapsing MS patients [12] , has been associated with an increased risk of PML [12] [13] [14] . Three risk factors for natalizumab-associated PML risk have been identified: the presence of anti-JCV antibodies, the duration of natalizumab treatment (particularly >2 years) and the prior use of immunosuppressants [13, 14] . To stratify PML risk in natalizumab-treated patients, Biogen developed an analytically validated enzyme-linked immunosorbent assay (the STRATIFY JCV™ assay, Focus Diagnostics, Cypress, CA, USA) to detect the presence of JCV antibodies in serum [15, 16] . An enhanced assay
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A N U S C R I P T 4 (STRATIFY JCV DxSelect™) in a new, easier-to-use kit format has been available since March 2012 [17] . This test has improved sensitivity to facilitate detection of anti-JCV antibody positive patients with low JCV antibody levels [17] . More recently, the level of anti-JCV antibodies in serum, as indicated by anti-JCV antibody index determined using the STRATIFY JCV DxSelect assay, has been shown to further delineate PML risk in patients without prior immunosuppressant use [14, 18] .
Rates of anti-JCV antibody seropositivity in MS patients show substantial variation, ranging from approximately 50% to 60% depending upon assay methodology, sample size, the age of the individuals studied and the types of populations studied [15, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . The JCV Antibody Epidemiology in MS (JEMS) study, which was conducted using the STRATIFY JCV assay, found a global anti-JCV antibody prevalence of 57.1% in MS patients from Europe, Canada and Australia [28] . In Portugal, JEMS enrolled 131 patients and found an anti-JCV antibody prevalence of 69.5% [29] , the highest level among European countries studied. This suggested a need for further studies of anti-JCV antibody prevalence in Portugal using a larger sample size and the newer STRATIFY JCV DxSelect assay.
The objectives of the JUSTIFY study were to determine the seroprevalence of anti-JCV antibody in Portuguese relapsing-remitting multiple sclerosis (RRMS) patients, to determine these patients' mean anti-JCV antibody index and to estimate the distribution of these patients by index threshold. In addition, the study aimed to identify required the second step of the assay to be conducted to determine positive or negative status [17] .
Statistical analysis
Prevalence values are presented along with their 95% confidence intervals (CIs).
As anti-JCV antibody index has been associated with PML risk only in patients without prior immunosuppressant use [14, 18] , only patients with no prior history of classical immunosuppressive therapies (azathioprine, methotrexate, mycophenolate mofetil, mitoxantrone, or cyclophosphamide) were considered when determining the mean anti-JCV antibody index and the patient distribution by index threshold. Patients were stratified into ≤0.9, >0.9 to ≤1.5 and >1.5 index cohorts.
Continuous variables were presented as mean ± standard deviation (SD), minimum and maximum. Categorical variables were described by the absolute and relative frequencies. Differences between independent categorical variables were tested using Pearson's chi-squared test. Student's t-test for independent samples was used to assess the statistical significance of differences between independent continuous variables. Results were considered significant at a 95% confidence level. All analyses were performed using R (version 3.1.0).
Results

Patients
A total of 655 patients were included in the study, 69.2% of whom were female.
At study evaluation visit, the mean age was 40.8 ± 11.0 years (range, 18-74 years), and MS duration varied from 0 to 36 years, with a mean of 7.7 ± 6.0 years. The mean age at MS diagnosis (n = 596) was 31.9 ± 10.3 years (range, 13-68 years), and most patients (93.3%) were under 50 years of age at diagnosis. At the time of the anti-JCV antibody tests considered for this analysis, the mean age was 39.5 years old, with the majority of patients under 40 years old (Table 1) .
Patients had a MS diagnosis for a mean of 6.6 years and EDSS scores prior to the JCV antibody serostatus evaluation of 0.0-7.5, with a mean of 2.8 (n = 619).
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A N U S C R I P T 8   Table 1 Disease and treatment characteristics at the time of the STRATIFY JCV DxSelect test (N = 655).
Characteristic
Overall study population Age, mean, years 39. A C C E P T E D M A N U S C R I P T 
At the time of the test, 31.5% of patients had been treated for ≤3 years, 41.7% had taken only one therapy for MS and 91.1% had no history of immunosuppressive treatment ( Table 1) . The most common therapy prior to or concurrent with the test was interferon beta-1a, followed by natalizumab and interferon beta-1b. Average treatment duration on natalizumab was 2.6 ± 1.7 years (n = 247).
The prevalence of anti-JCV antibodies
Of the 655 included patients, 398 tested anti-JCV antibody positive, for an overall prevalence of 60.8% (95% CI, 56.9-64.5). The association between seropositivity and clinical and demographic features is shown in Table 2 . Anti-JCV antibody seroprevalence was significantly higher in older patients, whereas it was not significantly related to gender (Table 2) or the patient's current or former area of residence (data not shown). It was also not significantly related to the duration of the disease or of treatment, both of which were similar in seropositive and seronegative patients. There was no significant difference in the prevalence of positive anti-JCV antibodies between immunosuppressant-naive and non-immunosuppressant-naive patients. Patients who had taken natalizumab before or at the time of the test were significantly less likely to be seropositive, though natalizumab treatment duration did not differ significantly between seronegative and seropositive patients ( A C C E P T E D M A N U S C R I P T 
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Anti-JCV antibody index
At the time of this study, physicians had to specifically request to receive information on anti-JCV antibody index. Thus, index data were not available for all patients; such data were collected for 430 of 655 patients in this study. In this subset of 
Anti-JCV antibody index in immunosuppressant-naive patients
Anti-JCV antibody index was available for 378 of 597 patients (63.3%) with no prior immunosuppressant use. For seropositive anti-JCV antibody immunosuppressantnaive patients (n = 270), 24.1% had an index ≤0.9, 12.2% had an index >0.9 and ≤1.5 and 63.7% had an index >1.5 ( Fig. 1) . Mean index values for negative (n = 108) and positive (n = 270) tests were 0.2 ± 0.1 and 2.1 ± 1.2, respectively. In the overall population of immunosuppressant-naive patients (including seronegative patients),
45.8% of patients had an index ≤0.9, 8.7% had an index >0.9 and ≤1.5 and 45.5% had an index >1.5. 
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Reasons for and influence of anti-JCV antibody tests in clinical practice
The most commonly reported reasons for performing the test were clinical characterization and the need to change medication (Table 3) . Of those tests motivated by a decision to change medication in which the clinician also predicted a potential next treatment (n = 169), natalizumab was the predicted next treatment in most cases (62.7%), followed by fingolimod (14.8%), 'second-line treatment' (11.2%), 'natalizumab
or fingolimod' (7.1%), interferon beta-1a or glatiramer acetate (1.1%) and 'to be decided' (3.0%).
Table 3
Motives for and impact of the anti-JCV antibody test. The test result had no impact on the subsequent treatment in 74.0% of cases based on physician records (Table 3 ). In those cases in which the test did influence treatment choice (Fig. 2) , the most common subsequent treatment (when known) was fingolimod (47.7%) or natalizumab (26.6%). Fingolimod was also most frequently 
Patient motives and impacts
Discussion
The overall prevalence of JCV antibody positivity in our study was 60.8% (95% CI, 57.0-64.7). Our calculations of anti-JCV antibody prevalence among Portuguese patients are lower than those identified in the JEMS study (69.5% [95% CI, 61.6-77.4]) [28, 29] , though the CIs partially overlap. Similarly, the results of our Portugal-wide study
are slightly lower than those of a recent single-centre Portuguese study conducted in 371 patients from Coimbra region, which reported an anti-JCV antibody seroprevalence of 68.2% [31] . However, our results showed a similar rate of seroprevalence when considering only the region included in that study (data not shown).
Although the anti-JCV antibody seroprevalence in this study was lower than in previous Portuguese studies [28, 29, 31] , we would still classify Portugal as a country with a high prevalence of anti-JCV antibody seropositivity. In JEMS, Portugal had the highest anti-JCV antibody seroprevalence among the 10 included European countries; using the estimates from our study, Portugal would rank fourth, after Germany, the Netherlands and Austria [28] . The estimated proportion of seropositive patients in this study is similar to the reported data from two multinational studies in Germany (59.1%
and 60.0%) [22, 28] and one of two studies in Sweden (59.0%) [22] . However, comparisons with these studies, as with the JEMS study, are limited by the use of the STRATIFY JCV assay in those studies and STRATIFY JCV DxSelect in the current study. While these two generations of the assay generally produce consistent results, STRATIFY JCV DxSelect has greater reproducibility and enhanced ability to detect low anti-JCV antibody responses [17] . Furthermore, the current study was a retrospective analysis of patients whose clinicians were interested in their anti-JCV antibody status.
The population may therefore have been biased toward patients who were receiving or were candidates for natalizumab treatment, limiting the seropositivity comparisons that can be made with populations in other studies.
A recent multicentre study in a Spanish cohort of 1061 MS patients found an anti-JCV antibody seropositivity rate of 58.2% [26] . In another multicentre study in Spain, an overall anti-JCV antibody seroprevalence of 55.3% was reported; however, when only
the samples analysed by the STRATIFY JCV DxSelect assay were considered, the prevalence (60.5%) was equivalent to the estimate in our cohort [27] . These two studies show apparent similarity in MS patients between two geographically proximate countries.
As in other studies, anti-JCV seropositivity was associated with greater age [19, 20, [22] [23] [24] [25] [26] [27] and was lower in women [19, [22] [23] [24] [25] 28, 29] , though we did not find a statistically significant difference between genders, as was observed in other studies [27, 31] . Consistent with the published results, anti-JCV antibody positivity was unrelated to MS duration [23, 24, 26, 28, 29] or the number or duration of MS treatments [23, 26, 28, 29] . Consistent with the published data that generally show no difference in seropositivity prevalence between immunosuppressant-naive and non-naive treated patients [19, 25, 26, 29] , the prevalence of positive anti-JCV antibodies did not differ between these two groups in our study.
In our study, patients who had taken natalizumab before or at the time of the test were significantly less likely to be seropositive than those who had not taken natalizumab. This is most likely due to the selection bias; as anti-JCV antibody positivity is a known PML risk factor, patients with a positive result are less likely to continue natalizumab and are therefore less likely to have available anti-JCV antibody tests.
In our study, 45.5% of patients without prior treatment with immunosuppressants had an anti-JCV antibody index >1.5. When conducting a risk-benefit assessment of natalizumab, it is important to consider the anti-JCV antibody index level in patients without prior immunosuppressant use, since PML risk can be further differentiated in these patients [14] . In patients with no prior immunosuppressant before starting natalizumab, the anti-JC virus antibody index level relates to the level of risk of PML.
The risk of PML is <1 per 1000 across all index groups during the first 2 years of treatment, and this risk remains low at antibody index ≤0.9, whereas it is substantially higher in patients with index >1.5 who have been treated with natalizumab for >2 years [14] .
It may not be necessary to exclude treatments with clinical impact, like natalizumab, in anti-JCV antibody positive patients. Indeed, many patients (40.1%) in this study were receiving or had previously received natalizumab at the time of the test.
Most of those on natalizumab treatment had received it for more than 2 years. In Our study has limitations that restrict the interpretation of some results. In addition to the potential selection bias mentioned above, we included only the last anti-JCV antibody test results using the STRATIFY JCV DxSelect assay, which did not allow us to evaluate longitudinal changes in seroprevalence and the effects of specific treatments.
Conclusions
We found a 60.8% seroprevalence of anti-JCV antibodies in 655 Portuguese  Anti-JC virus antibody prevalence was significantly higher in older patients.
 Clinicians did not exclude natalizumab as an option for seropositive patients.
 Results support the benefit-risk assessment of natalizumab in Portuguese patients.
